Buzzard Pharmaceuticals Overview
- Year Founded
-
2016
- Status
-
Out of Business
- Employees
-
5
- Latest Deal Type
-
Out of Business
Buzzard Pharmaceuticals General Information
Description
Developer of a pharmaceutical drug designed to be used for cancer treatment. The company is licensed with the rights to develop a recombinant protein, Isunakinra, for cancer indications, and plans to reposition drugs in oncology, enabling medical professionals and organizations to gain further access to cancer indications.
Contact Information
Website
www.buzzardpharma.comCorporate Office
- Skeppsbron 16
- 111 30 Stockholm
- Sweden
Corporate Office
- Skeppsbron 16
- 111 30 Stockholm
- Sweden
Buzzard Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Out of Business | 22-Nov-2025 | Completed | Out of Business | |||
| 2. Later Stage VC | 01-Jan-2022 | Completed | Generating Revenue | |||
| 1. Later Stage VC | 14-Sep-2021 | $5.94M | $5.94M | Completed | Clinical Trials - Phase 2 |
Buzzard Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary |
Buzzard Pharmaceuticals Comparisons
Industry
Financing
Details
Buzzard Pharmaceuticals Competitors (4)
One of Buzzard Pharmaceuticals’s 4 competitors is Swedish Orphan Biovitrum, a Formerly VC-backed company based in Stockholm, Sweden.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Swedish Orphan Biovitrum | Formerly VC-backed | Stockholm, Sweden | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY | ||||
| Cantargia | Formerly VC-backed | Lund, Sweden |
Buzzard Pharmaceuticals Patents
Buzzard Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022445159-A1 | Inhibitor of interleukin-1 receptor type 1 for use in the treatment of cancer | Pending | 10-Mar-2022 | ||
| US-20250188162-A1 | Inhibitor of interleukin-1 receptor type 1 for use in the treatment of cancer | Pending | 10-Mar-2022 | ||
| WO-2023169686-A1 | Inhibitor of interleukin-1 receptor type 1 for use in the treatment of cancer | Inactive | 10-Mar-2022 | ||
| ES-2884813-T3 | Chimeric cytokine formulations for ocular administration | Active | 13-Mar-2013 | ||
| AU-2014243839-A1 | Chimeric cytokine formulations for ocular delivery | Active | 13-Mar-2013 | A61K47/10 |
Buzzard Pharmaceuticals Signals
Buzzard Pharmaceuticals FAQs
-
When was Buzzard Pharmaceuticals founded?
Buzzard Pharmaceuticals was founded in 2016.
-
Where is Buzzard Pharmaceuticals headquartered?
Buzzard Pharmaceuticals is headquartered in Stockholm, Sweden.
-
What is the size of Buzzard Pharmaceuticals?
Buzzard Pharmaceuticals has 5 total employees.
-
What industry is Buzzard Pharmaceuticals in?
Buzzard Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Buzzard Pharmaceuticals a private or public company?
Buzzard Pharmaceuticals is a Private company.
-
What is Buzzard Pharmaceuticals’s current revenue?
The current revenue for Buzzard Pharmaceuticals is .
-
How much funding has Buzzard Pharmaceuticals raised over time?
Buzzard Pharmaceuticals has raised $11.6M.
-
Who are Buzzard Pharmaceuticals’s competitors?
Swedish Orphan Biovitrum, Novartis, Regeneron Pharmaceuticals, and Cantargia are competitors of Buzzard Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process